A practical reference on Reverse-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-11. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
CH3C(O)CO2− + HCO3− + ATP → −O2CCH2C(O)CO2− + ADP + Pi Occurring in the mesophyll of plants, this process proceeds via phosphoenolpyruvate, catalysed by phosphoenolpyruvate carboxylase. Oxaloacetate can also arise from trans- or de- amination of aspartic acid.
A variety of serotonergic psychedelics have been assessed and found to produce neurotoxicity at high concentrations in vitro and/or high doses in vivo in rodents. These psychedelics have included DOI, 2C-B, 25B-NBOMe, 25C-NBOMe, 5-MeO-DiPT, 5-MeO-MiPT, methallylescaline (MAL), and BOD, among others. The neurotoxicity induced by the preceding psychedelics has included MDMA-like serotonergic neurotoxicity, for instance with DOI, MAL, and 5-MeO-DiPT. The neurotoxicity of psychedelics has been found to be partially blocked by serotonin 5-HT2A receptor inhibition, which was also the case with the neurotoxicity of MDMA. Besides producing neurotoxicity on their own, psychedelics have been found to potentiate the serotonergic neurotoxicity of MDMA via serotonin 5-HT2 receptor activation in rodents. DOM is known to metabolize into 2,5-DDM-DOM (2-O-,5-O-didesmethyl-DOM; 2,5-dihydroxy-4-methylamphetamine), which bears a close resemblance to 6-hydroxydopamine (6-OHDA; 2,4,5-trihydroxyphenethylamine) and has been found to be a potent neurotoxin similarly. Other related phenethylamine psychedelics may also undergo similar metabolism and form analogous potentially neurotoxic metabolites. Chronic administration of LSD has been associated with long-lasting schizophrenia-like behavioral changes in rodents, which was not blocked by serotonin 5-HT2A receptor antagonism but may instead be related to LSD's dopamine D2-like receptor agonism.
=== Cancer === Water-soluble polymer shells are being created to deliver a protein, apoptin, into cancer cells. The protein goes into the nucleus of the cancer cells while leaving healthy cells alone, unlike other conventional therapies as gene therapies and chemotherapy. The capsules are 100 nm in size. Active targeting of cancer cells is also being researched. Through active targeting, the nanocapsules form ligands that bind to malignant cells for cell delivery. This method is especially beneficial for those drugs that are not as permeable through the cell membrane, and where tissues are diseased, the nanoparticles are able to bond easier with the malignant cells.
Sources: en.wikipedia.org
... had deteriorated to the point where the Soviet Union as a system—not just the Kremlin, not just Soviet leader Yuri Andropov, not just the KGB, but as a system—was geared to expect an attack and to retaliate very quickly to it. It was on hair-trigger alert. It was very nervous and prone to mistakes and accidents. The false alarm that happened on Petrov's watch could not have come at a more dangerous, intense phase in U.S.–Soviet relations. In an interview aired on American television, Blair said, "The Russians [Soviets] saw a U.S. government preparing for a first strike, headed by a President Ronald Reagan capable of ordering a first strike." Regarding the incident involving Petrov, he said, "I think that this is the closest our country has come to accidental nuclear war."
=== Table of modes of action and classes of insecticide === In the table the number of insecticides listed in each class is given, and an example of each class. The number of insecticides in the IRAC class listing as of 2024 is given in column Nr (A). The number in the Compendium of Pesticide Common Names (insecticide + acaricide) is given in column Nr (B), although the name given there to the class historically is often different to the IRAC class name.
The properties of nanoparticles often differ markedly from those of larger particles of the same substance. Since the typical diameter of an atom is between 0.15 and 0.6 nm, a large fraction of the nanoparticle's material lies within a few atomic diameters of its surface. Therefore, the properties of that surface layer may dominate over those of the bulk material. This effect is particularly strong for nanoparticles dispersed in a medium of different composition since the interactions between the two materials at their interface also becomes significant. Nanoparticles occur widely in nature and are objects of study in many sciences such as chemistry, physics, geology, and biology. Being at the transition between bulk materials and atomic or molecular structures, they often exhibit phenomena that are not observed at either scale. They are an important component of atmospheric pollution, and key ingredients in many industrialized products such as paints, plastics, metals, ceramics, and magnetic products. The production of nanoparticles with specific properties is a branch of nanotechnology. In general, the small size of nanoparticles leads to a lower concentration of point defects compared to their bulk counterparts, but they do support a variety of dislocations that can be visualized using high-resolution electron microscopes. However, nanoparticles exhibit different dislocation mechanics, which, together with their unique surface structures, results in mechanical properties that are different from the bulk material.
Sources: en.wikipedia.org
=== Medications that cause or worsen myasthenia gravis === Antibiotics: In the macrolide family of antibiotics, azithromycin, telithromycin (which is no longer available in the U.S. market), and erythromycin are reported to exacerbate myasthenia gravis. In the fluoroquinolone antibiotic family, ciprofloxacin, norfloxacin, ofloxacin, and moxifloxacin are reported to exacerbate myasthenia gravis. And, In the aminoglycoside family of antibiotics, gentamicin, streptomycin, and neomycin are reported to exacerbate myasthenia gravis. The aminoglycoside tobramycin has not been reported to exacerbate myasthenia gravis and may be used in people that require aminoglycoside treatment. Because of the rarity or absent reports on their exacerbation of myasthenia gravis, the following antibiotics are considered safe to use in people with myasthenia gravis: the cephalosporin class of drugs, sulfa drugs, the tetracycline group of drugs, clindamycin, polymyxin B, and nitrofurantoin. Immune checkpoint inhibitors: Immune checkpoint inhibitors promote certain types of autoimmune responses by blocking checkpoint pathways that inhibit these responses. They are used to treat cancers that promote their own growth and spread by stimulating checkpoint pathways. These checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, and durvalumab. From a total 5,898 people who received these drugs, 52 developed new onset myasthenia gravis and 11 had a flare of their preexisting myasthenia gravis.
1993/616) Magistrates' Courts (Reciprocal Enforcement of Maintenance Orders) (Miscellaneous Amendments) Rules 1993 (S.I. 1993/617) Maintenance Orders (Reciprocal Enforcement) Act 1992 (Commencement) Order 1993 (S.I. 1993/618) Public Trustee (Fees) (Amendment) Order 1993 (S.I. 1993/619) Child Maintenance (Written Agreements) Order 1993 (S.I. 1993/620) Children (Admissibility of Hearsay Evidence) Order 1993 (S.I. 1993/621) High Court (Distribution of Business) Order 1993 (S.I. 1993/622) Maintenance Orders (Backdating) Order 1993 (S.I. 1993/623) Children (Allocation of Proceedings) (Amendment) Order 1993 (S.I. 1993/624) Education (Listed Bodies) Order 1993 (S.I. 1993/625) Education (Recognised Bodies) Order 1993 (S.I. 1993/626) Family Proceedings Courts (Child Support Act 1991) Rules 1993 (S.I. 1993/627) Education (Queen Elizabeth Atherstone Further Education Corporation) (Dissolution) Order 1993 (S.I. 1993/628) National Board for Nursing, Midwifery and Health Visiting for England (Constitution and Administration) Order 1993 (S.I. 1993/629) Motor Vehicles (Type Approval and Approval Marks) (Fees) Regulations 1993 (S.I. 1993/630) A65 Trunk Road (Hellifield and Long Preston Bypass and Slip Roads) Order 1993 (S.I. 1993/631) A65 Trunk Road (Bigholmes Lane to Switchers) (Detrunking) Order 1993 (S.I. 1993/632) National Board for Nursing, Midwifery and Health Visiting for Scotland Order 1993 (S.I. 1993/637) Lothian and Central Regions and West Lothian and Falkirk Districts (Mannerston/Cauldcoats Holdings and M9 Motorway) Boundaries Amendment Order 1993 (S.I.
Vitamin K: CID 5280483 from PubChem Vitamin K1 (phylloquinone, phytomenadione): CID 5284607 from PubChem Vitamin K2 (menaquinone 6): CID 5283547 from PubChem Vitamin K3 (menadione): CID 4055 from PubChem
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.